The NMPA designation advances NHWD-870 HCI, an oral BET inhibitor for advanced thoracic NUT carcinoma, following Phase II data showing anti-tumour activity and survival benefit in a rare, aggressive cancer with limited treatment options. ...
The Tokyo office will support Japanese biopharmaceutical companies across the product lifecycle, combining market access, medical, marketing and strategic consulting capabilities under the leadership of Junji Yokokawa. ...
The new x-ray irradiator uses tomosynthesis-based 3D imaging and faster dose delivery to make targeted preclinical radiotherapy studies more accessible to research laboratories. ...
India Sebia, in collaboration with CAHO Diagnostic Division, is proud to announce the launch of the Autoimmunity Masterclass Series—a six-part academic webinar initiative aimed at advancing the understanding, early diagnosis, and clinical management of autoimmune diseases....
Industry veteran to lead marketing strategy and strengthen commercial execution...
Together, these announcements represent a step forward in increasing accessibility to complex DNA...
‘Avishkar’, the innovative platform of the conference, emerged as a focal point for creative problem solving, with participants presenting pioneering ideas ranging from novel medical devices to AI-driven healthcare solutions...
Expanded offering enhances accessibility and personalisation in hearing solutions for veterans through integrated platform...
New triple-taper femoral system aims to enhance stability, versatility, and surgical efficiency...
New robotic microtomy solution targets efficiency and scalability in laboratory tissue processing...
